Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Biohaven’s protein degrader is promising in early IgAN trial, heads straight to Phase 3
5 months ago
AbbVie partners with Simcere Pharma unit to develop myeloma drug
5 months ago
Pharma
Hengrui and Kailera’s injected incretin posts best-in-class obesity data in Phase 2 trial
5 months ago
Gilead taps into STAT6 space via $250M deal with Leo Pharma
5 months ago
Deals
Regor’s obesity pill posts muted weight loss in Phase 2a, enters new trial
5 months ago
Bayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to Phase 3 trial
5 months ago
Pfizer touts bladder cancer results as first advancement for some patients 'in decades'
6 months ago
Pharma
FDA+
Dyne details pivotal plans for myotonic dystrophy RNA drug, though data blip worries some investors
6 months ago
Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs
6 months ago
Marea reports early Phase 2 data for cholesterol-lowering drug it licensed from Novartis
6 months ago
IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint
6 months ago
People
Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment
6 months ago
Pharma
FDA+
Tenpoint reveals positive Phase 3 data for vision drug after Visus merger
6 months ago
Aiolos team reunites with $411M for new biotech with obesity drugs from China
6 months ago
Financing
Startups
MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment
6 months ago
Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago
6 months ago
Cell/Gene Tx
Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request
6 months ago
FDA+
Astellas stops developing autologous cell therapy using tech from Xyphos buyout
6 months ago
Pharma
Cell/Gene Tx
‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies
6 months ago
Financing
Vir’s early T cell engager data offer first look at cancer pivot, stock jumps
6 months ago
Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround
6 months ago
People
With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding
6 months ago
Jasper reports more data in spontaneous hives from tiny study
6 months ago
Calico, Denali's ALS drugs miss primary objectives in basket study
6 months ago
First page
Previous page
16
17
18
19
20
21
22
Next page
Last page